August 6, 2025 - 23:19

Tenaya Therapeutics has announced significant progress in its clinical trials, marking a pivotal moment for its innovative therapies targeting specific heart conditions. The enrollment process for Cohorts 1 and 2 of the MyPEAK™-1 Phase 1b/2 trial of TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy (HCM), has been successfully completed. This achievement has been bolstered by a positive safety review from the Data Safety Monitoring Board (DSMB), which has now allowed the company to proceed with the enrollment of expansion cohorts.
In addition, the RIDGE™-1 Phase 1b trial of TN-401 has also made strides, with Cohort 1 fully enrolled and the first patient with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) dosed in Cohort 2. This advancement follows the DSMB's recommendation to escalate dosing and expand the trial.
Tenaya Therapeutics is set to provide data readouts from both clinical programs in the fourth quarter of 2025, with a cash runway projected to extend into the second half of 2026, ensuring continued development of these promising therapies.
October 5, 2026 - 08:04
The Promises Developers Made to Cleveland in Exchange for Financial HelpSince Cleveland strengthened a city law in 2023, the city has signed 52 Community Benefits Agreements with developers seeking public financial support. These agreements are part of an effort to...
October 4, 2026 - 18:37
Mountain Scholars program shifts financial management to CMC FoundationThe Mountain Scholars program, which provides support for first-generation college students in Summit County, will begin a new chapter this fall. The Colorado Mountain College Foundation is set to...
October 4, 2026 - 10:00
Single Mother Earns $100,000 in a Year Through Superannuation StrategyA single mother from Australia has managed to earn $100,000 within just 12 months by taking a hands-on approach to her superannuation, a move that reflects a broader shift in how people are...
October 3, 2026 - 21:26
The Coming AI Bust Could Trigger a Financial BloodbathThe rapid surge of capital into artificial intelligence infrastructure has created conditions that some analysts compare to a bubble on the verge of bursting. Billions of dollars are being poured...